drugset / Trial / NCT02169817

Evaluation Of Bacillus Clausii In Treatment Of Acute Diarrhea In Latin American Children

NCT02169817

Phase 4 Completed 629 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To demonstrate the effectiveness of treatment with Bacillus clausii probiotic strain (Enterogermina) in combination with oral rehydration therapy (ORT) for a period of 5 days, in the duration of acute community-acquired diarrhea in Latin American children. Secondary Objectives: To evaluate the clinical safety of Enterogermina in acute diarrhea in children and to demonstrate its effectiveness on stool frequency, stool consistency, and number of vomiting episodes. To evaluate parent's overall global assessment. To evaluate the safety and effectiveness of Enterogermina in norovirus acute gastroenteritis (AGE).

Timeline

Start
2014-07
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bacillus clausii Other / unclassified 2 unknown Oral

Indications